Emerging research suggest Retatrutide , a dual stimulator targeting both incretin and another hormone, could provide a significant step forward for body treatment. Preliminary clinical tests have indicated considerable reductions in visceral mass , conceivably outperforming other obesity treatments. However , additional study is required to complet